Search
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. … It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.
Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalEnzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. … Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667]
Categories: Androgen Receptor Antagonists, Androgen Receptor InhibitorsRemoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawn[A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Categories: Dopamine D2 Receptor AntagonistsPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. … Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.
Categories: Serotonin Receptor Agonists, Serotonin-4 Receptor AgonistProducts: RESOLOR ® TABLETAS RECUBIERTAS DE 2 MG, RESOLOR ® TABLETAS RECUBIERTAS DE 1 MGCemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigationalCemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. … By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
Categories: Programmed Death Receptor-1 Blocking AntibodyBromotheophylline
go.drugbank.com/drugs/DB14018Approved[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.
Nitroglycerin
go.drugbank.com/drugs/DB00727ApprovedInvestigational[L42445] It is also used to induce intraoperative hypotension.[L7099] … [A180166,A180172] Its use as a treatment for angina dates back to 1879 and is still used to treat and prevent angina.[A249970] Nitroglycerin causes vasodilation in both arteries and veins.
Products: NITROGLICERINA PH&TTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours. … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration
Synonyms: HuMax-TF-ADCNedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigationalThis approval is based on the favorable results from the pivotal phase 2 PHYOX<sup>TM</sup>2 and interim data from the ongoing phase 3 PHYOX<sup>TM</sup>3 clinical trials.[L48325] … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.